Recent studies focused on prognosis of COVID‐19 concluded that the load of SARS‐CoV‐2 RNA in blood (RNAemia) is correlated with Cytokine Release Storm (CRS) and poor prognosis of the disease. In one particular study, scientists used Generalized Linear Models to generate a prediction model for natural history of disease based on the C t value of real‐time RT‐PCR results. They reported that traceable amounts of SARS‐CoV‐2 RNA was detected in blood plasma of 15% of COVID‐19 positive patients enrolled at the study. Their findings drew a direct link between serum markers and disease severity, as RNAemia and high levels of IL‐6 (nearly 10‐fold) were exclusively reported in critically ill patients. Interestingly, there was also an association between the extremely high levels of IL‐6 with the incidence of RNAemia (R = 0.902) in patients. Findings also suggested that vital signs of patients were also affected by high levels of both serum markers (R = 0.682). According to this study, IL‐6 might be of clinical value in identification and treatment of patients with an excessive inflammatory response (Chen, Zhao, et al., 2020). Table 3 (Chen, Zhao, et al., 2020; Yan et al., 2020) and Table 4 represent 2020 studies on prognosis of COVID‐19 infected patients and related clinical trials, respectively.